ČINČÁROVÁ, Lenka, Zbyněk ZDRÁHAL a Jiří FAJKUS. New perspectives of valproic acid in clinical practice. Expert Opinion on Investigational Drugs. Abingdon-on-Thames: TAYLOR & FRANCIS LTD, 2013, roč. 22, č. 12, s. 1535-1547. ISSN 1354-3784. Dostupné z: https://dx.doi.org/10.1517/13543784.2013.853037. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1138417, author = {Činčárová, Lenka and Zdráhal, Zbyněk and Fajkus, Jiří}, article_location = {Abingdon-on-Thames}, article_number = {12}, doi = {http://dx.doi.org/10.1517/13543784.2013.853037}, keywords = {CAR; combination therapy; HDAC inhibition; radiosensitization; TRAIL/Apo2L; valproic acid}, language = {eng}, issn = {1354-3784}, journal = {Expert Opinion on Investigational Drugs}, title = {New perspectives of valproic acid in clinical practice}, url = {http://informahealthcare.com/doi/abs/10.1517/13543784.2013.853037}, volume = {22}, year = {2013} }
TY - JOUR ID - 1138417 AU - Činčárová, Lenka - Zdráhal, Zbyněk - Fajkus, Jiří PY - 2013 TI - New perspectives of valproic acid in clinical practice JF - Expert Opinion on Investigational Drugs VL - 22 IS - 12 SP - 1535-1547 EP - 1535-1547 PB - TAYLOR & FRANCIS LTD SN - 13543784 KW - CAR KW - combination therapy KW - HDAC inhibition KW - radiosensitization KW - TRAIL/Apo2L KW - valproic acid UR - http://informahealthcare.com/doi/abs/10.1517/13543784.2013.853037 L2 - http://informahealthcare.com/doi/abs/10.1517/13543784.2013.853037 N2 - Introduction: Valproic acid (VPA) has been used in clinical practice as an anticonvulsant for more than four decades. Its pharmacokinetics and toxicity are thus well documented. VPA is also a potent class-selective histone deacetylase (HDAC) inhibitor at nontoxic therapeutic concentrations. New areas of application for VPA are currently opening up in clinical practice. Areas covered: The authors discuss VPA and how it may serve as an effective drug for cancer therapy. This is due to its ability to induce differentiation of a number of cancer cells in vitro and also to decrease tumor growth and metastases in animal models. The authors highlight how the utilization of VPA as an HDAC inhibitor is not limited to a single-agent therapy. Early clinical studies have also revealed promising potency of VPA in combination treatment with classic anticancer drugs. The authors do this by summarizing the published results and providing insight into the potential future developments for this field. Expert opinion: VPA was shown to restore or improve responsiveness of tumors to conventional therapeutic agents, to enhance the efficacy of adenoviral gene therapy, to sensitize TRAIL-resistant tumor cells to apoptosis, and to enhance radiosensitivity of tumor cells. Drawbacks in VPA medical applications include its teratogenicity and complexity of its effects. ER -
ČINČÁROVÁ, Lenka, Zbyněk ZDRÁHAL a Jiří FAJKUS. New perspectives of valproic acid in clinical practice. \textit{Expert Opinion on Investigational Drugs}. Abingdon-on-Thames: TAYLOR \&{} FRANCIS LTD, 2013, roč.~22, č.~12, s.~1535-1547. ISSN~1354-3784. Dostupné z: https://dx.doi.org/10.1517/13543784.2013.853037.
|